Safety and Immunogenicity of Flu-M Quadro in Healthy Volunteers

Phase 1, randomised, single-blind trial of Flu-M Quadro in influenza (3 arms), sponsored by Saint Petersburg Scientific Research Institute of Vaccines and Serums. Primary endpoints: Incidence of adverse events (local and systemic post-vaccination reactions) and Incidence of any serious adverse events during the trial. Started Nov 2019; status: completed.